and given part of your statement celg isnt worth 150 well that is either a man afraid or a man who is more bear than bull and i think it is the latter because imo celg goes thru 150 with ease latter this yr
i dont care for your excuses as far as i am concerned you sound like a man afraid of his own shadow i have seen you do this in fb as well so go ahead tell me you are a genius on fb as well what looks like duck and talks like a duck and smells like a duck must be a duck
I have been in CELG for years now. I probably know this company better then anyone here. I am the bears best friend because I want to buy shares cheaper. I bought my 50% trading position back below $114 down to $110. I took it off at $134.50. Right now, I do want it to go back to $110. I can buy it back again and wait for the next pop. CELG is the greatest biotech on Earth in my book. I have had my core position for some 200+% now. I have also added another 133% in trading gains to that. I love using the volatility of the market to make more money. If your afraid of CELG going back down to $110, then you have issues not me. I would love for that opportunity to reload. All I am doing is embracing the fact that the market can be very irrational at times. Does CELG deserve to go to $100? Certainly not. Is it worth $150? I think not based on my valuation calculations. I have been in this stock a long time, and I know its historical valuation ranges. Right now $137.50 is my year end price target.
i think when u talk 120 it gives bears momentum and it gives way to 110 and pretty soon the stock is in freefall i think people like you are the bears best friend you are afraid of your own shadow and are the type who will run fast if the stock starts falling being afraid of your own shadow gives emphasis to people to bet against you i have seen you do this samer i am afraid speach on other boards Do yourself a favor and stop talking bearish talk
So you think everyone should go around all the time wearing rose colored glasses and ignoring all of the negatives. I say that is a setup for failure. You can love a company like CELG, and remain objective so you don't get blindsided by possible risks. Stocks go up and down. There is no harm in trading around your core position to amplify gains. Anyone who thinks stocks only go up is just irrational. Does CELG go to $120? I don't know. Does it go to $150? I don't know. I do know I am prepared for either.
i hate people who say they are bulls but talk nothing but bearish talk you arent going to see 120 unless the whole mkt falls alot and i dont see that as of yet of course if the fed raises interest rates now with all the negativity out there then maybe you might see some big correction other wise give it up with your bear nonesense
Biotech is mostly bad across the board this week. FBIOX has lost $35 per share or almost half it's yearly gain in the last three weeks.
If you noticed this morning, Kyle Bass and CELG are ramping up for their big patent fight this fall. Anyone who has followed this ordeal over the past few years knows Kyle has no case. He is shorting companies and attacking patents just to attempt to make money. It worked for him for a while when CELG sold off in April/May but he is in the house of pain now. This will clearly weight on the stock. I would expect this to become more prominent as we get closer to the case this fall. There is no reason to race out and buy here for long term. You can be patient and wait for the market to bring it to your price. Fore me, That is at $120 or below which is my fair value calculation based on trailing twelve months earnings. I have given up in this market on trying to trade short term. I am just waiting for that good pullback that give me a great entry point to put back on my trading position. Personally, I am watching the RSI. I like to buy when it hits oversold and sell when it hits overbought. Right now, it sites at 47 which is in no mans land. China, Europe, Fed, and fear are all good reason to be patient right now.
Not safe at all, getting killed again today on China devaluing again another 2%. If China does it again tomorrow, everything is sunk, our whole market is sunk. If you didn't think China owned us, you should now.
3 days of positive MACD moves confirms a short term up trend occurring within a longer term down trend on the 5 year chart. I would expect the stock to take back some of this correction over the next week or two. Much of that depends on the overall market, but Biotech is a safe haven from the fears of slower global growth. People don't stop taking medications because China devalued its currency. I will try with all honesty to try and keep you all updated if the trend stalls or changes.
What's up Rob. Haven't seen you on these forums for long time. What brings you back?
Full Cowen rpt...CELG - a large cap top pick- Preparing To Dominate Heme/Onc For A Long Time...Ozanimod Highly Attractive Product Profile...P&L Offers Good Leverage..
Cowen and Company
Equity Research Quick Take: Company Update
August 11, 2015
Price Target: $150.00
Preparing To Dominate Heme/Onc For A Long Time To Come
The Cowen Insight
Last week we hosted a meeting with Celgene’s President & COO Mark Alles, CFO Peter Kellogg, and IR Director Lisa Hayes. With Revlimid leading the way, management was particularly bullish on its ~10-year growth outlook, and is increasing focused on building a leading heme/onc franchise that will sustain growth beyond Revlimid's eventual patent expiration. CELG remains a top large cap biotech pick. Revlimid’s Future Looks Bright...
Management remains confident that Revlimid is positioned to be the backbone of Multiple Myeloma (MM) therapy with multiple datasets now showing that continuous Rev/dex treatment is superior to multiple other myeloma regimens. In addition, several trials now built upon the Rev/dex backbone with triple combinations (Rev/ dex + a novel therapy) setting a new standard for efficacy. Management noted three growth drivers in particular that provides confidence on the longer-term commercial outlook for Revlimid (1) Duration gains: management notes that essentially all new drugs are being evaluated on top of continuous Rev/dex regimen, and as these new therapies improves PFS, the duration of Revlimid treatment will also benefit. In addition, multiple trials have also shown that continuous Rev/dex treatment is superior to fixed duration Rev/dex treatment, thereby prompting additional physicians to alter their prescribing patterns. Recall that the average duration of Revlimid dosing is 19-20 months in the U.S. versus a company goal of ~24 months. In Europe, duration is only 9-10 months and we don’t see any reason why duration couldn't eventually approximate U.S. levels; (2) Market share gains: management mentioned that new scrips are setting records despite the typical adverse summer seasonality, and attributed this growth to the recent newly diagnosed multiple myeloma (NDMM) claim in the U.S. In Europe, though Revlimid is still very early in its NDMM launch and the majority of country-by-country reimbursement is still on the come, early trends are very favorable and significant market share gains are expected. Current market share in Europe is
imo celg is on its way to 150 fast it is easy to love this stock yet some say they are bullish and cont to post negative nonesense
Why do you post this nonsense? Otezla is still double step edited. Do you get that? It has to fail 2 of the preferred biologics before patients can't get it. It remains in the same position as last year, buried as a third choice.
Use your power to get a single PBM or MCO to put it at parity with a biologic and sales will soar.
I know you see Bob around town. Make it so.